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ORIGINAL INVESTIGATION
Oral treatment with a zinc complex 
of acetylsalicylic acid prevents diabetic 
cardiomyopathy in a rat model of type‑2 
diabetes: activation of the Akt pathway
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Abstract 
Background: Type‑2 diabetics have an increased risk of cardiomyopathy, and heart failure is a major cause of death 
among these patients. Growing evidence indicates that proinflammatory cytokines may induce the development 
of insulin resistance, and that anti‑inflammatory medications may reverse this process. We investigated the effects 
of the oral administration of zinc and acetylsalicylic acid, in the form of bis(aspirinato)zinc(II)‑complex Zn(ASA)2, on 
different aspects of cardiac damage in Zucker diabetic fatty (ZDF) rats, an experimental model of type‑2 diabetic 
cardiomyopathy.
Methods: Nondiabetic control (ZL) and ZDF rats were treated orally with vehicle or Zn(ASA)2 for 24 days. At the age 
of 29–30 weeks, the electrical activities, left‑ventricular functional parameters and left‑ventricular wall thicknesses 
were assessed. Nitrotyrosine immunohistochemistry, TUNEL‑assay, and hematoxylin‑eosin staining were performed. 
The protein expression of the insulin‑receptor and PI3K/AKT pathway were quantified by Western blot.
Results: Zn(ASA)2‑treatment significantly decreased plasma glucose concentration in ZDF rats (39.0 ± 3.6 vs 
49.4 ± 2.8 mM, P < 0.05) while serum insulin‑levels were similar among the groups. Data from cardiac catheterization 
showed that Zn(ASA)2 normalized the increased left‑ventricular diastolic stiffness (end‑diastolic pressure–volume 
relationship: 0.064 ± 0.008 vs 0.084 ± 0.014 mmHg/µl; end‑diastolic pressure: 6.5 ± 0.6 vs 7.9 ± 0.7 mmHg, P < 0.05). 
Furthermore, ECG‑recordings revealed a restoration of prolonged QT‑intervals (63 ± 3 vs 83 ± 4 ms, P < 0.05) with 
Zn(ASA)2. Left‑ventricular wall thickness, assessed by echocardiography, did not differ among the groups. However 
histological examination revealed an increase in the cardiomyocytes’ transverse cross‑section area in ZDF compared 
to the ZL rats, which was significantly decreased after Zn(ASA)2‑treatment. Additionally, a significant fibrotic remod‑
eling was observed in the diabetic rats compared to ZL rats, and Zn(ASA)2‑administered ZDF rats showed a similar 
collagen content as ZL animals. In diabetic hearts Zn(ASA)2 significantly decreased DNA‑fragmentation, and nitro‑
oxidative stress, and up‑regulated myocardial phosphorylated‑AKT/AKT protein expression. Zn(ASA)2 reduced cardio‑
myocyte death in a cellular model of oxidative stress. Zn(ASA)2 had no effects on altered myocardial CD36, GLUT‑4, 
and PI3K protein expression.
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Background
Diabetes mellitus (DM) is a metabolic disorder charac-
terized by chronic hyperglycemia due to an impairment 
of insulin secretion, defects of insulin action, or both. The 
increasing prevalence of DM, and its association with 
cardiovascular disease have become serious public health 
issues. Primarily, the complications of diabetes have been 
attributed to increased atherosclerosis. However, DM is 
also able to alter the cardiac structure and function in 
the absence of coronary atherosclerosis, hypertension 
and significant valvular disease [1], a condition called 
diabetic cardiomyopathy (DCM) [2, 3]. Depending on its 
cause, diabetes can be classified into two main catego-
ries, type-1 and type-2 DM. More than 90 % of diabetic 
patients are diagnosed with type-2 diabetes dominated 
by hyperinsulinemia, hyperglycemia and dyslipidemia. 
Additionally, about 80  % of type-2 diabetic patients are 
overweight or obese. Importantly, obesity is not only 
associated with lipid accumulation in adipose tissue, but 
also in non-adipose tissues such as the myocardium. This 
lipid overload in the cytoplasm of the cells may cause cel-
lular dysfunction, cell death, eventual cardiac dysfunc-
tion and heart failure, and also may be an explanation for 
DCM [4–6]. Additionally, the direct effects of hypergly-
cemia on cardiomyocytes and oxidative stress due to the 
production of reactive oxygen species and nitrogen spe-
cies, have also been proposed to be the root cause under-
lying the development of DCM [7]. Furthermore, recent 
studies have revealed that proinflammatory cytokines 
can cause the sustained development of insulin resistance 
[8], and that anti-inflammatory medications may reverse 
this process [9, 10]. Thus therapeutic interventions tar-
geting free radical generation, inflammation, and/or 
endogenous antioxidant enzymes enhancement, and gly-
cemic metabolism by using insulin-enhancing or insulin-
mimetic agents would be useful in patients with type-2 
DM at risk for developing DCM.
In recent years some metal ions and their complexes 
have been proposed as candidates for treating DM. Zinc 
is an essential trace element for the synthesis, storage, 
and release of insulin [11]. Orally active zinc(II)-com-
plexes have been found to have in vitro insulinomimetic 
activity and an in vivo blood glucose lowering effect [12]. 
In addition to glycemic control, zinc(II) ions are known to 
possess anti-ulcer activities as well as anti-inflammatory 
properties [13]. Therefore, the dietary supplementation 
of zinc has been recommended as a novel strategy to 
manage diabetes-associated cardiac complications [14]. 
The proposed molecular mechanism of zinc consists of 
the activation of the entire insulin signalling pathway, 
including the activation of protein kinase B (also known 
as AKT), a serine/threonine-specific protein kinase. 
Thus, lipogenesis is increased and the glucose trans-
port (GLUT)-4 protein is translocated to the cell mem-
brane, facilitating the uptake of glucose into the cell 
[11]. Moreover, antioxidant activities of zinc complexes 
have been described [15–17], implying the activation of 
antioxidant enzymes, the attenuation of oxygen-derived 
free radicals, and the generation of free radicals scaven-
gers. A high dose of salicylates has been found to reverse 
hyperglycemia and hyperinsulinemia in type-2 diabetic 
patients [10]. Therefore, the zinc complex of acetylsali-
cylic acid (aspirin) (Zn(ASA)2) was synthesized [18]. The 
anti-inflammatory effect of aspirin can be increased, the 
gastrointestinal absorption of aspirin may be enhanced, 
the ulcergenicity of aspirin may be reduced, and zinc can 
be presented in a better tolerated dosage form. Recently, 
it has been shown that the synergic effect of zinc and 
aspirin, in the form of bis(aspirinato)zinc(II) complex 
improved not only hyperglycemia, insulin resistance, 
leptin resistance, and hypoadiponectinemia, but also 
improved hypertension in type-2 diabetic KK-Ay mice 
[19]. However, experimental investigations of the effects 
of the zinc complex of acetylsalicylic acid on diabetic 
hearts using in vivo animal models are yet lacking.
The Zucker diabetic fatty (ZDF) rat is the most widely 
used type-2 diabetic obese rodent model. At the age of 
25 weeks ZDF rats develop a severe metabolic syndrome 
associated with profound modifications of the cardiac 
transcriptome, which may be involved in the develop-
ment of cardiac pathology [20]. Additionally, old ZDF 
rats show gender-related differences, such as female 
rodents are less susceptible to high-fat diet-induced insu-
lin resistance, that might be relevant to humans [21].
One of the therapeutic options concerning diabetic 
patients without cardiovascular disease or with ischemic 
heart disease, includes aspirin treatment. We hypoth-
esized that the use of zinc and aspirin in the form of 
bis(aspirinato)Zinc(II) complex, may be a new treat-
ment concept for these patients due to its blood glucose 
Conclusions: We demonstrated that treatment of type‑2 diabetic rats with Zn(ASA)2 reduced plasma glucose‑levels 
and prevented diabetic cardiomyopathy. The increased myocardial AKT activation could, in part, help to explain the 
cardioprotective effects of Zn(ASA)2. The oral administration of Zn(ASA)2 may have therapeutic potential, aiming to 
prevent/treat cardiac complications in type‑2 diabetic patients.
Keywords: Cardiac function, Diabetic cardiomyopathy, Type‑2 diabetes mellitus, Zinc‑aspirin complex
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lowering function [19], cardioprotective actions [22], and 
preventive effects against restenosis [23]. In light of these 
findings, we investigated the effects of an oral administra-
tion of the zinc complex of acetylsalicylic acid upon dia-
betes-induced changes in cardiac structure, function, and 
electrical activity. As the AKT-GLUT-4 signalling path-
way has been found to be activated by zinc complexes, we 
also investigated whether their protein expressions play a 
crucial role in our experimental setting.
Methods
Animals
Male Zucker diabetic fatty (ZDF) rats and Zucker lean 
(ZL) control rats were obtained at an age of 12  weeks 
(Charles River, Saint Germain-Nuelles, France). The 
Animals were kept in local facilities, housed in standard 
cages with 12 h light/dark cycles at a constant tempera-
ture of 22 ± 2 °C, a Purina 5008 diet, as recommended by 
the supplier, was fed with water ad libitum. Both the care 
of the animals and the experimental procedures were 
conducted according to the ‘Principles of Laboratory 
Animal Care’ drafted by the National Society for Medical 
Research and the ‘Guide for the Care and Use of Labo-
ratory Animals’, prepared by the Institute of Laboratory 
Animal Resources and published by the National Insti-
tute of Health (NIH Publication No. 86-23, revised 1996). 
The experiments were approved by the Ethical Commit-
tee of the Land Baden-Württemberg for Animal Experi-
mentation (G-56/13).
Rat model of type‑2 DM
The ZDF male rat (fa/fa) is genetically inbred and devel-
ops obesity, fasting hyperglycemia, and type-2 diabe-
tes (ZDF group, n  =  13) while fed a special diet. The 
homozygous (+/+) and heterozygous (fa/+) Zucker gen-
otypes remain lean (ZL group, n = 20). Based on litera-
ture data and the results of our previous studies [24, 25], 
final experiments on the rats were performed at an age of 
29–30 weeks.
Experimental groups
At the age of 25–26  week-old the rats were randomly 
divided into four groups: (1) ZL group (n = 10): ZL rats 
received a polyethylene glycol vehicle, (2) ZDF group 
(n  =  7): ZDF rats received a polyethylene glycol vehi-
cle, (3) ZDF + Zn(ASA)2 group (n = 6): ZDF rats were 
treated with Zn(ASA)2, and (4) ZL  +  Zn(ASA)2 group 
(n = 10): ZL rats received Zn(ASA)2. Zn(ASA)2 was pre-
pared as a suspension in a polyethylene glycol vehicle at a 
volume of 2 ml/kg. It was administered once daily, by oral 
gavage, for 24 days at the dose of 15 mg/kg. The applica-
tion and dosage of Zn(ASA)2 were determined according 
to the results of previous rodent experiments [19]. The 
experimental protocol is shown in Fig. 1.
Echocardiography
One day before the final experiments, the rats were 
slightly anesthetized with 1.5–2.0 % isoflurane by mask, 
the left side of the chest was shaved to obtain a clear 
image, and the animals were situated in the supine posi-
tion on a warming pad. Two-dimensional (long- and 
short-axis) and motion-mode (M-mode) images of the 
left ventricle were obtained from a parasternal view, car-
ried out with vevo 2100 ultrasound system, and using 
standard echocardiography. All data was analysed off-line 
at the end of the study, with the software resident on the 
ultrasound system. Interventricular diameters includ-
ing left ventricular internal end-diastolic dimensions 
(LVIDd) and left ventricular internal end-systolic dimen-
sions (LVIDs), were measured. All measurements were 
based on the mean of at least three consecutive cardiac 
cycles on the M-mode tracing at the level of the papillary 
muscle, and the mean values were used in our analyses.
Electrocardiogram (ECG) recording
The rats were anesthetized with sodium pentobarbi-
tal (60  mg/kg) intraperitoneally, and they were kept in 
a supine position. Their body temperature (measured 
via rectal probe) was maintained at 37  °C. The stand-
ard 12-lead electrocardiogram (leads I, II, III, aVR, aVL, 
aVF, V1, V2, V3, V4, V5, and V6) was recorded using 
subcutaneously placed needle electrodes. All leads were 
connected to a standard direct-writing recorder (Mor-
tara Instrument, WI, USA). The paper speed was set at 
50  mm/s, and the sensitivity at 10  mm/mV. The ECG 
analysis was evaluated by lead II including the following 
measurements: ST-segment elevation, QRS complex, and 
QT-intervals. The QT-interval, measured from the onset 
of the QRS complex to the end of the T wave, was cor-
rected using the normalized Bazett’s formula adjusted for 
rats (nQTc = QT/(RR/f )1/2) (RR corresponding to cardiac 
cycle length and f to frequency) [26]. The electrocardiog-
raphy was analyzed by an examiner blinded to the experi-
mental groups.
In vivo hemodynamic measurements and cardiac function
After the ECG recording, the animals were tracheot-
omised, intubated, and artificially ventilated. A polyeth-
ylene catheter was inserted into the left external jugular 
vein for fluid administration purposes. A 2F microtip 
pressure–volume catheter (SPR-838, Millar Instruments, 
Houston, TX, USA) was inserted into the right carotid 
artery and advanced into the ascending aorta. After 
allowing an initial stability period of 5  min, the systolic 
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blood pressure (SBP), diastolic blood pressure (DBP), 
mean arterial pressure (MAP), and heart rate were 
recorded. After that, the catheter was advanced into the 
left ventricle under pressure control. With the use of a 
special pressure–volume analysis program (PVAN, Millar 
Instruments, Houston, TX, USA), stroke volume, cardiac 
output (CO), stroke work, left-ventricular end-systolic 
pressure (LVESP), left-ventricular end-diastolic pressure 
(LVEDP), and time constant of left-ventricular (LV) pres-
sure decay (Τau) were calculated. The pressure–volume 
relations of the LV cavity were assessed by briefly com-
pressing the inferior vena cava. The slope [end-systolic 
elastance (Ees)] of the LV end-systolic pressure–volume 
relationship (ESPVR) according to the parabolic curvi-
linear model [27] was calculated as a load-independent 
index of LV contractility. The slope of the LV end-dias-
tolic pressure–volume relationship (EDPVR) was calcu-
lated as a reliable index of LV stiffness.
Biochemical estimation
After the heart function was measured the blood was 
collected from the abdominal aorta in Lithium-Heparin-
Gel Monovette® and serum tubes. Then, after centrifu-
gation, plasma and serum samples were obtained. The 
levels of plasma glucose, high-density lipoprotein (HDL) 
cholesterol, total cholesterol, triglyceride and aspartate 
aminotransferase (AST) were determined in the cen-
tral laboratory of the Heidelberg University clinic on an 
ADVIA 2400 chemistry analyser (Siemens, Germany). 
The levels of serum insulin were measured via ELISA kit 
(Mercodia, Uppsala, Sweden) and non-esterified fatty 
acids were determined with a commercially available 
enzymatic and colorimetric assay kit (Wako Chemicals, 
Germany). Fast protein liquid chromatography (FPLC) 
was used for the analysis of lipoprotein profiles. Serum 
samples from each experimental group were pooled and 
separated by chromatography on an ÄKTApurifier FPLC 
system (GE Healthcare, Sweden). Briefly, 400 μl of pooled 
serum were separated using a Superose-6 size exclusion 
column, and the eluate was fractionated. Total choles-
terol and triglyceride contents of the individual fractions 
were determined via commercially available kits (Randox 
Laboratories, UK and Human Diagnostica, Germany, 
respectively).
Histopathological process
After the blood samples were collected pieces of myo-
cardial tissue were fixed in a buffered paraformaldehyde 
solution (4  %), embedded in paraffin, and cut to 5-μm. 
All of the histological evaluations were conducted by an 
examiner blinded to the experimental groups.
Hematoxylin and eosin staining
Paraffin-embedded sections were placed on adhesive 
slides and stained with hematoxylin and eosin. Cardio-
myocyte cross-sectional areas were calculated under a 
microscope using the Cell^A software (Olympus Soft 
Imaging Solutions GmbH, Germany).
Fig. 1 Experimental protocol. At the age of 25–26 week‑old, ZL or ZDF rats were treated with Zn(ASA)2 or a polyethylene glycol vehicle (15 mg/kg) 
orally for 24 consecutive days. Zn(ASA)2 indicates a zinc complex of acetylsalicylic acid, ZDF Zucker diabetic fatty rats, ZL Zucker lean
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Terminal deoxynucleotidyl transferase‑mediated dUTP nick 
end‑labeling (TUNEL)
TUNEL assay was performed according to the manufac-
turer’s instructions (Chemicon International, Temecula, 
CA, USA), to detect DNA strand breakages (free 3′-OH 
DNA ends). Briefly, the rehydrated sections were digested 
with 20 μg/ml DNase-free Proteinase K (Sigma-Aldrich, 
Germany) to retrieve antigenic epitopes, and endogenous 
peroxidases were blocked with 3  % hydrogen peroxide 
(H2O2). The free 3ʹ-OH termini of the DNA ends were 
labeled with a reaction mixture of terminal deoxynucle-
otidyl transferase (TdT) and digoxigenin-dUTP at 37  °C 
for 1  h (Chemicon International, Temecula, CA, USA). 
Incorporated digoxigenin-conjugated nucleotides were 
detected using a horseradish peroxidase conjugated anti-
digoxigenin antibody and 3,3ʹ-diaminobenzidine. The 
sections were counterstained with Gill’s hematoxylin. 
Dehydrated sections were cleared in xylene, mounted 
with Permount (Fischer Scientific, Germany), and cover-
slips were applied. Based on the intensity and distribution 
of the labelling, a semi-quantitative histomorphological 
assessment was performed using conventional micros-
copy. For the assessment of TUNEL-labelled cells, the 
number of positive cell nuclei per microscopic examina-
tion field (with 200× magnification) was counted in four 
fields for each sample, averaged, and the mean was calcu-
lated for each experimental group.
Acid fuchsin orange G (AFOG)
An AFOG-stain was used to detect collagen fibers in the 
heart tissue. Histological sections were automatically 
imaged, using 20× magnification (resolution: 0.46  μm/
pixel), with the Hamamatsu NanoZoomer 2.0-HT Scan 
System (Hamamatsu Photonics, Hamamatsu Japan). The 
slide scanner automatically detects the region of interest 
containing the tissue, and also automatically determines 
a valid focal plane for scanning. Image processing algo-
rithms have been developed using VisiomorphDP version 
4.5.1.324 (Visiopharm, Hoersholm, Denmark). Image pro-
cessing was performed in several distinguished steps: (a) 
Automatic region of interest detection using thresholding 
methods in the RGB-Colorspace. As a result of this step, 
the tissue regions are separated from the background for 
further analysis; (b) Pixelwise classification of the whole 
slide by using a linear Bayesian Classifier [28] in RGB col-
orspace. After training the classifier by manually marking 
background areas within the tissue regions, the normal 
muscle tissue, as well as the fibrotic areas, the classifier 
was able to separate the processed area into one of these 
three subcategories. A second subsequent classifier was 
trained to detect folded tissue and artifacts; (c) As a post-
processing step, areas that were too small (small tissue 
fragments, staining artifacts, dust particles) were removed 
by using morphological operations like opening and clos-
ing. The ratio of the fibrotic area in relation to the total 
tissue can be calculated using these output variables.
Immunohistochemical detection of nitrotyrosine
According to previously described methods [29] we per-
formed immunohistochemical staining on heart tissue to 
detect nitrotyrosine, a marker for nitro-oxidative stress. 
Positive immunohistological staining was scored using 
semiquantitative analysis. The total score was then given 
based on the sum of the intensity and the area scores. 
The intensity was evaluated as follows: no staining (score 
0), weak staining (score 1), moderate staining (score 2), 
and severe staining (score 3). The area score was evalu-
ated (from 0 to 4) within score 0 representing no stain-
ing, score 1 (positive cells <10 %), score 2 (positive cells 
11–50  %), score 3 (positive cells 51–80  %) and score 4 
(positive cells >80 %).
Western blotting
Proteins were extracted from the heart tissue in a 1x RIPA 
buffer (Melford, Ipswich, UK). The protein concentra-
tion was determined with Bradford assay. Total protein 
homogenates 20  μg/30  μl were denatured, separated on 
sodium dodecyl sulfate polyacrylamide electrophoresis 
gels, and transferred to a polyvinylidene fluoride mem-
brane (Millipore, Darmstadt, Germany). The membrane 
was blocked with 2.5  % BSA in Tris- Buffered Saline 
Tween 20 for 1  h, before being incubated overnight at 
4 °C with CD36 (1:1000, Cell Signalling Technology, Cam-
bridge, UK), GLUT-4 (1:100, Santa Cruz, Biotechnology, 
Heidelberg, Germany), insulin receptor-β (1:1000, Cell 
Signalling Technology, Cambridge, UK), phosphorylated-
PI3K (1:1000, Cell Signalling Technology, Cambridge, UK), 
PI3K (1:1000, Cell Signalling Technology, Cambridge, UK), 
AKT, or phosphorylated-AKT (1:500, Abcam, Cambridge, 
UK). After washing the blots to remove excessive primary 
antibody binding, the blots were incubated for 1 h with a 
horseradish peroxydase conjugated secondary antibody 
at room temperature. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), housekeeping protein, was used for 
loading control and protein normalization. The immuno-
reactive protein bands were developed using the Enhanced 
Chemiluminescence system (PerkinElmer, Rodgau-Jue-
gesheim, Germany). The intensity of the immunoblot 
bands was detected with Chemismart 5100.
Cellular model of hydrogen peroxide‑induced 
cardiomyocytes oxidative stress
Isolation and culture of neonatal rat cardiomyocytes, 
measurement protocol
Neonatal cardiomyocytes were isolated from 1- to 2-day-
old newborn rats (Charles River, Sulzfeld, Germany). 
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Briefly, the hearts were excised and rapidly placed into 
an ice-cold buffer (in mmol/L: NaCl 116.4, HEPES 20, 
NaH2PO4 1, glucose 5.5, KCl 5.4, MgSO4 0.8; pH 7.4). 
The atria and great vessels were trimmed and discarded. 
The ventricles were cut into small pieces and incubated 
(37 °C, 20 min) repeatedly (5 to 6 times) in a buffer sup-
plemented with collagenase type II (Worthington Bio-
chemical Corporation, New Jersey, USA) and pancreatin 
(0.6 mg/mL; Gibco BRL). After each round of digestion, 
the supernatant was centrifuged (1200  rpm, 10  min), 
and the resulting cell pellet was resuspended in DMEM/
M199 (4:1) supplemented, with 5  % horse serum (Bio-
chrom, Berlin, Germany), 10 % fetal bovine serum (Gibco 
by Thermo Fischer Scientific, Karlsruhe, Germany), 
penicillin G (100  U/mL; Gibco by Thermo Fischer Sci-
entific, Karlsruhe, Germany), and streptomycin (100 μg/
mL; Gibco by Thermo Fischer Scientific, Karlsruhe, Ger-
many). Then, cells were pooled and separated on a dis-
continuous Percoll (GE Healthcare Bio-Sciences AB, 
Uppsala, Sweden) gradient (top density  =  1.059  g/ml, 
bottom density  =  1.082  g/ml) by centrifugation. The 
middle band at the interface of the two Percoll layers 
was collected. Cell damage was estimated based on lac-
tate dehydrogenase activity released from damaged cells 
into the cell culture, using a colorimetric lactate dehy-
drogenase-Cytotoxicity Assay kit (BioVision, CA, USA). 
The absorbance was measured at 490–500  nm using a 
plate reader (Thermo Labsystems Multiskan Ascent, 
MD, USA), and the percentage of cytotoxicity was then 
calculated.
Experimental groups
To investigate the effects of Zn(ASA)2 upon H2O2-
induced oxidative stress in cardiomyocytes, the cul-
tured neonatal cardiomyocytes were divided into two 
groups: (1) vehicle  +  H2O2 group (n  =  25 wells): car-
diac cells were pre-treated with the vehicle (DMSO, 2 h), 
then incubated with H2O2; (2) Zn(ASA)2 + H2O2 group 
(n  =  25 wells): cells were pre-treated with Zn(ASA)2 
(10−3 M; 2 h), then incubated with H2O2. The concentra-
tion of H2O2 was 500 µM, the incubation time was 2 h.
Statistics
All data is expressed as mean  ±  standard error of the 
mean (SEM). Intergroup comparisons were performed 
by using one-way analysis of variance, followed by a Stu-
dent’s unpaired t test with Bonferroni’s correction for 




The plasma glucose levels were significantly higher in 
ZDF rats compared to ZL animals (49.4  ±  2.8  mM vs. 
11.8  ±  0.7  mM, P  <  0.05), indicating the manifestation 
of an overt diabetes. When ZDF rats received daily oral 
administration of Zn(ASA)2 for 24 days, the plasma glu-
cose levels were significantly reduced in comparison to 
ZDF rats (Table  1). Total cholesterol, HDL cholesterol, 
and free non-esterified fatty acid levels were significantly 
higher in ZDF rats than in ZL rats, and the Zn(ASA)2 
treatment provided no changes. Additionally, triglycer-
ide levels in the diabetic group were significantly elevated 
compared to both ZL groups. Treatment with Zn(ASA)2 
further significantly increased plasma triglyceride con-
centrations in the diabetic rats, while having no effect 
upon the lean group. As the triglycerides were abnor-
mally high, the LDL cholesterol calculation could not be 
performed. Therefore, the serum lipoproteins were sepa-
rated by fast performance liquid chromatography (FPLC). 
Three major peaks were detected, representing the 
lipoprotein classes VLDL, LDL, and HDL, respectively 
(Fig. 2). Peak size analysis confirmed increased levels of 
HDL (Table  1; Fig.  2) and showed high VLDL and LDL 
Table 1 Biochemical parameters
Biochemical profile of ZDF (Zucker diabetic fatty) and Zucker Lean (nondiabetic) rats after 24 days of treatment with either vehicle or zinc complex of acetylsalicylic 
acid (Zn(ASA)2). Values are mean ± SEM. * P < 0.05 vs ZL, # P < 0.05 vs ZDF, $ P < 0.05 vs ZL + Zn(ASA)2









Plasma glucose (mmol/L) 11.8 ± 0.7 49.4 ± 2.8*$ 39.0 ± 3.6*#$ 11.4 ± 0.7
Plasma HDL cholesterol (mmol/L) 0.27 ± 0.01 1.96 ± 0.11*$ 1.83 ± 0.06*$ 0.28 ± 0.02
Plasma total cholesterol (mmol/L) 2.56 ± 0.13 8.68 ± 0.89*$ 9.27 ± 0.95*$ 2.24 ± 0.14
Plasma triglycerides (mmol/L) 1.0 ± 0.2 13.5 ± 1.1*$ 17.4 ± 1.3*#$ 1.1 ± 0.1
Non‑esterified fatty acid (mmol/L) 0.21 ± 0.04 0.45 ± 0.07*$ 0.49 ± 0.09*$ 0.22 ± 0.01
Serum insulin (μg/L) 0.75 ± 0.10 0.71 ± 0.08 0.70 ± 0.09 1.33 ± 0.25
Plasma GOT/AST (U/L) 64 ± 4 77 ± 12 107 ± 26 81 ± 4
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(Fig. 2) in diabetic rats. The administration of Zn(ASA)2 
had further increased VLDL levels, while there was no 
effect on LDL cholesterol. Furthermore, serum insulin 
levels were similar among the groups with a tendency 
toward increase in the nondiabetic control group treated 
with Zn(ASA)2. Plasma GOT/AST concentrations, which 
show the degree of hepatic disturbance, were also identi-
cal to those of the untreated rats.
General characteristics and LV wall thickness
During 24  days of treatment, the ZL rats gained 
(+0.20  ±  2.8  g), whereas the ZDF rats lost weight 
(−75  ±  38  g), without reaching statistical significance 
(P  >  0.05). Treatment with Zn(ASA)2 had no effect 
on body weight loss (ZDF  +  Zn(ASA)2: −17  ±  6  g; 
ZL  +  Zn(ASA)2: −7  ±  2  g). Furthermore, the body 
weight, heart weight, heart-to-body weight ratio, and 
heart weight-to-tibia length ratio were similar among the 
groups (Table 2). LV wall thickness, assessed by echocar-
diography, did not differ among the groups (Table 2).
Zn(ASA)2 improves ECG patterns
In ECG recordings, type-2 DM was associated with an 
elongated corrected QT-interval for heart rate, reduced 
PQ-interval, and moderate ST-segment elevation com-
pared to ZL rats. Treatment with Zn(ASA)2 significantly 
reduced the prolonged corrected QT-interval and ST-
segment elevation (Fig. 3).
Zn (ASA)2 improves LV cardiac function
Basic hemodynamic data
The heart rate, systolic and diastolic blood pressures, 
mean arterial pressure, and the cardiac output were simi-
lar among all the experimental groups (Table 3).
Fig. 2 Total cholesterol and triglyceride levels of fast performance liquid chromatography (FPLC) fractions. The graph shows a cholesterol and b 
triglyceride concentrations of FPLC fractions from pooled serum. Zn(ASA)2 indicates a zinc complex of acetylsalicylic acid, ZDF Zucker diabetic fatty 
rats, ZL Zucker lean, VLDL very low density lipoprotein, LDL low density lipoprotein, HDL high density lipoprotein
Table 2 Body weight, heart weight, heart-to-body weight ratio, heart weight-to-tibia length ratio and  left-ventricular 
wall thickness assessed by echocardiography
Values are mean ± SEM. ZL indicates Zucker lean, ZDF Zucker diabetic fatty acid, Zn(ASA)2 zinc complex of acetylsalicylic acid, LVPW, d, thickness of the left ventricular 










 Body weight (g) 419 ± 9 376 ± 18 394 ± 27 416 ± 6
 Heart weight (g) 1.36 ± 0.03 1.22 ± 0.04 1.35 ± 0.14 1.32 ± 0.03
 Heart‑to‑body weight (g/kg) 3.26 ± 0.05 3.26 ± 0.11 3.39 ± 0.10 3.19 ± 0.07
 Heart weight‑to‑tibia length (g/cm) 0.32± 0.01 0.30 ± 0.01 0.33 ± 0.03 0.30 ± 0.01
Left‑ventricular wall thickness
 LVPW, d (mm) 2.49 ± 0.31 2.95 ± 0.42 1.95 ± 0.17 1.94 ± 0.20
 LVPW, s (mm) 3.20 ± 0.27 4.24 ± 0.40 3.16 ± 0.19 2.69 ± 0.25
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Systolic function
The stroke volume, stroke work, and LVESP did not differ 
among the groups (Table 3). Figure 4 shows representa-
tive original pressure–volume loops registered during 
transient occlusion of the inferior vena cava. The end-
systolic pressure–volume relationship of the diabetic rats 
demonstrated only slightly decreased slope (Ees) in com-
parison to that of the ZL animals (Table 3).
Diastolic function
Increased slope of EDPVR and the LVEDP in ZDF ani-
mals suggested a markedly increased LV diastolic stiff-
ness (Fig.  4). Moreover, these passive diastolic function 
parameters were similar in ZL and ZDF + Zn(ASA)2 ani-
mals. The LV active relaxation as assessed by Tau-w did 
not differ among the groups (Table 3).
Zn(ASA)2 decreases cardiomyocyte hypertrophy
Histological examination revealed that the cardiomyo-
cyte transverse cross-section area in the ZDF rats was 
significantly increased in the H&E stained sections com-
pared to the ZL animals (Fig. 5a, b). This enlargement was 
significantly decreased after the Zn(ASA)2 treatment.
Zn(ASA)2 decreases nitro‑oxidative stress
A significant increase in nitrotyrosine production could 
be observed in ZDF rats when compared with ZL ani-
mals. Treatment with Zn(ASA)2 significantly decreased 
nitrotyrosine production, as testified by decreased brown 
staining (Fig. 5a, c).
Effect of Zn(ASA)2 on myocardial fibrosis
The histopathologic examination of myocardial tissue, 
using acid fuchsin orange G-stain (AFOG), revealed a 
significant increase in fibrotic formation in ZDF rats 
compared to ZL animals. ZDF rats treated with Zn 
(ASA)2 showed a collagen content comparable to the ZL 
groups (Fig. 6a–c).
Zn(ASA)2 decreases DNA strand breaks
A significant increase in the density of TUNEL-positive 
cell nuclei was observed in the myocardium of ZDF rats 
compared to ZL animals, indicating DNA-fragmenta-
tion. Treatment with Zn(ASA)2 significantly decreased 
the percentage of myocardial cells with DNA damage 
(Fig. 6d–g).
Fig. 3 Zn(ASA)2 improves electrocardiographic pattern. a Representative surface 12‑lead ECG tracing; b corrected QT interval; c PQ‑interval, and 
d ST‑segment elevation. Values are mean ± SEM, n = 6‑10. *P < 0.05 vs ZL, #P < 0.05 vs ZDF, $P < 0.05 vs Zn(ASA)2, nQTc = QT/(RR/f )1/2. Zn(ASA)2 
indicates a zinc complex of acetylsalicylic acid, ZDF Zucker diabetic fatty rats, ZL Zucker lean, RR corresponding to cardiac cycle length and f to 
frequency, nQTc QT intervals corrected with RR intervals
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Zn(ASA)2 regulates myocardial protein expression
Western blot analysis (Fig.  7) revealed that the expres-
sion of CD36 was significantly increased, and GLUT-4 
was decreased in ZDF rats compared to the nondia-
betic group. The insulin receptor β expression was simi-
lar among the groups. Zn(ASA)2 had no effect on these 
proteins. Even though there was no significant change in 
phosphorylated-PI3K, type-2 DM promotes the expres-
sion of total PI3K compared to the control, but the ratio 
remained unchanged. Additionally, despite no signifi-
cant alteration in phosphorylated and total AKT, ZDF 
rats showed a significant decrease in phosphorylated-
AKT/AKT ratio compared to the ZL group. Treatment 
with Zn(ASA)2 significantly decreased total AKT and 
considerably increased the phosphorylated-AKT/AKT 
expression.
Zn(ASA)2 reduces the cytotoxicity induced by H2O2 
in cardiomyocytes
H2O2, at a concentration of 500  μM, induced 73 ±  2  % 
cytotoxicity in cultured neonatal cardiomyocytes, which 
was significantly decreased to 26 ± 1 % after a pre-treat-
ment of cardiac cells with Zn(ASA)2.
Discussion
The aim of this study was to investigate the effects of 
the oral administration of zinc and aspirin, in the form 
of bis(aspirinato)zinc(II) complex on diabetes-induced 
cardiac damage. Our results suggest that its blood glu-
cose lowering effect with increased activation of the 
serine-threonine kinase AKT in the myocardium could, 
in part, explain the cardioprotective effects of Zn(ASA)2 
upon DCM.
DCM has been defined as ventricular dysfunction 
along with abnormal myocardial structure in the absence 
of changes in blood pressure and coronary artery dis-
ease. Multiple pathophysiological mechanisms have been 
proposed to explain this phenomenon, such as myocar-
dial fibrosis, myocyte hypertrophy, contractile dysfunc-
tion, changes in calcium handling and in mitochondrial 
function, abnormal cardiomyocyte loss by apoptosis 
and unsuccessful metabolic adaptation [30]. Despite all 
these mechanisms, hyperglycemia is considered to be 
one of the main pathogenic mechanisms of DCM. The 
potential role of a zinc complex of acetylsalicylic acid in 
treating DM has recently been demonstrated. An orally 
administered complex of zinc and aspirin ameliorated 
hyperglycemia and metabolic syndrome-like disorders 
in an animal model of type-2 DM [19]. The anti-diabetic 
effect of Zn(ASA)2 is also supported by our findings in 
ZDF rats, which showed that a treatment with Zn(ASA)2 
caused a significant reduction of high plasma glucose lev-
els. However, its administration did not have a significant 
impact on the lipid profile, except that the VLDL-triglyc-
eride levels were increased further by the treatment. It 
might be that the Zn(ASA)2 lowers blood glucose levels 
by enhancing the conversion of excess glucose to triglyc-
erides in the liver. However, we do not have unequivo-
cal evidence at this point, and further investigations are 
needed to clarify these metabolic aspects of Zn(ASA)2 
Table 3 Hemodynamic parameters
In vivo cardiac catheterization findings of ZDF (Zucker diabetic fatty) and Zucker lean (nondiabetic) rats after 24 days of treatment with either vehicle or Zn(ASA)2. 
Values are mean ± SEM, * P < 0.05 vs. ZL, $ P < 0.05 vs. ZL + Zn(ASA)2
Zn(ASA)2 indicates a zinc complex of acetylsalicylic acid, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean blood pressure, CO cardiac output, LVESP 
left ventricular end systolic pressure, Ees the slope Ees of the left ventricular end‑systolic pressure–volume relationship, Tau time constant of left ventricular decay, n 










 Heart rate (beats/min) 366 ± 12 346 ± 14 355 ± 12 373 ± 13
 SBP (mmHg) 138 ± 5 151 ± 6 153 ± 6 141 ± 7
 DBP (mmHg) 106 ± 3 108 ± 7 110 ± 5 107 ± 6
 MAP (mmHg) 112 ± 4 122 ± 7 124 ± 5 118 ± 6
 CO (ml/min) 31.0 ± 2.8 35.6 ± 5.3 35.6 ± 2.3 30.2 ± 4.1
Systolic function
 Stroke volume (µl) 85 ± 7 93 ± 13 100 ± 5 81 ± 11
 Stroke work (mmHg*ml) 8.56 ± 0.88 10.71 ± 1.28 11.25 ± 0.78 7.86 ± 1.09
 LVESP (mmHg) 131 ± 5 131 ± 6 128 ± 7 133 ± 7
 Ees (mmHg/µl) 1.13 ± 0.13 0.75 ± 0.11 0.85 ± 0.06 1.18 ± 0.24
Diastolic function
 Tau (Weiss) (ms) 9.8 ± 0.3 10.3 ± 0.7 10.2 ± 0.3 9.9 ± 0.4
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treatment. Its underlying mechanisms involve glucose 
uptake into the adipocytes by facilitating insulin’s binding 
to its receptor, leading to the activation of insulin recep-
tor β-subunit, insulin receptor substrates, PI3K which in 
turn activates protein kinase B/AKT. Thus, the transloca-
tion of GLUT-4 to the adipocytes membrane stimulated 
by insulin, normalizes blood glucose levels in the experi-
mental diabetic animals [31]. In the present study set up, 
Zn(ASA)2 does not influence insulin production how-
ever, the small amounts of insulin released by the pan-
creas can be more effective after a Zn(ASA)2 treatment. 
Furthermore, the insulin-mimetic activity of zinc com-
plexes was previously examined in terms of free fatty acid 
release, and was found to inhibit free fatty acid release 
from isolated rat adipocytes treated with epinephrine 
(adrenaline) [31], also indirectly indicating their in vitro 
glucose-uptake ability into the cells.
Metabolic abnormalities present in diabetes (hyperin-
sulinemia, hyperlipidemia, and hyperglycemia) might be 
the initial event which causes endothelial dysfunction, 
inflammation, apoptosis, and oxidative stress [32]. In 
the present study, we demonstrated in an in vitro model, 
Fig. 4 Zn(ASA)2 improves left‑ventricular cardiac function. a Representative original pressure–volume loops registered during transient occlusion 
of the inferior vena cava. The slope of end‑systolic pressure–volume relationship (red line) and end‑diastolic pressure–volume relationship (EDPVR, 
green line); b the slope of end‑diastolic pressure–volume relationship (EDPVR); and c left‑ventricular end‑diastolic pressure (LVEDP). Values are 
mean ± SEM, n = 6–10. *P < 0.05 vs ZL, #P < 0.05 vs ZDF, $P < 0.05 vs Zn(ASA)2. Zn(ASA)2 indicates a zinc complex of acetylsalicylic acid, ZDF Zucker 
diabetic fatty rats, ZL Zucker lean
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that Zn(ASA)2 protects cardiomyocytes from oxidative 
stress-induced damage. Furthermore, the presence of 
nitrotyrosine on proteins in the diabetic myocardium, 
as shown by our immunohistochemical staining, as a 
marker for nitro-oxidative stress in vivo, is in agreement 
with previous data [33, 34]. According to the semi-quan-
titative scoring of the staining, pronounced nitro-oxida-
tive stress can be prevented by a Zn(ASA)2 treatment. 
Other studies supporting our observations have shown 
that zinc-induced overexpression of the antioxidant 
protein metallothionein protects the heart against dia-
betes-induced cardiac protein nitration in the develop-
ment of DCM [35]. Zinc supplementation was sufficient 
to prevent DCM at least partially by reducing oxidative 
stress [36]. Molecular events of oxidative stress are lipid 
peroxydation [37], protein oxidation [38], and oxidative 
damage of DNA [39]. One of the most widely used meth-
ods for detecting DNA breaks and DNA fragmentation in 
tissue sections is TUNEL, which was described to detect 
cells undergoing apoptosis [40]. Oxidative stress-induced 
cell deaths, such as apoptosis, have important roles in 
the pathogenesis of DCM. In the present study, upon 
treatment of diabetic rats with Zn(ASA)2, the number 
of cardiac apoptotic nuclei was significantly decreased. 
In addition, apoptosis contributes to the loss of cardiac 
myocytes leading to adverse cardiac remodeling, includ-
ing fibrosis and hypertrophy, impaired cardiac function, 
and eventually heart failure. The accumulation of extra-
cellular matrix proteins, in particular collagens is one 
of the key processes in DCM. Sárközy et al. have shown 
an altered expression of several genes related to cardiac 
hypertrophy and remodeling [41]. Minerals, vitamins, 
and trace elements treatment in diabetic rats resulted 
in opposite gene expression changes, showing benefi-
cial effects in DCM [41]. In the present study enhanced 
nitro-oxidative stress and apoptosis in the diabetic 
Fig. 5 Zn(ASA)2 decreases cardiomyocyte hypertrophy and nitro‑oxidative stress. a Hematoxylin and eosin staining micrographs of transverse sec‑
tions of myocardium (magnification ×400; scale bar: 50 μm) and representative photomicrographs of nitrotyrosine immunohistochemistry staining; 
magnification ×200, scale bar: 20 µm. b Quantitative analysis of cardiomyocyte cross‑sectional area using of ~20 cardiomyocytes in each group and 
c immunohistochemical scores for nitrotyrosine in the myocardium. Values are mean ± SEM, n = 6–9. *P < 0.05 vs ZL, #P < 0.05 vs ZDF, $P < 0.05 vs 
Zn(ASA)2. Zn(ASA)2 indicates a zinc complex of acetylsalicylic acid, ZDF Zucker diabetic fatty rats, ZL Zucker lean
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myocardium, and a high histopathological cardiac fibro-
sis score were shown in accordance with the literature, 
and were proven to be normalized by a Zn(ASA)2 treat-
ment. Despite the ability of the antihyperglycemic agents, 
such as metformin and sulfonylureas, to maintain nor-
moglycemia, many patients still develop DCM or are at 
risk for cardiovascular events [30]. To overcome these 
limitations and drawbacks for the use of conventional 
metabolic treatments, the findings of the present study 
may open novel therapeutic strategies, using Zn(ASA)2 
directed against DCM.
Structural changes of the myocardium are often 
referred to as remodeling [42]. The main feature of this 
process is an increase in ventricular mass and at cellular 
level the hypertrophy of individual cardiomyocytes. An 
increase in myocyte profile surface area, as evident in the 
present work through enlarged cardiomyocytes in dia-
betic rats, has been observed. Potential causes of cardio-
myocyte hypertrophy have been accredited to a number 
of factors, including mechanical stress [43], the sympa-
thetic nervous system [44], the renin-angiotensin-aldos-
terone system [43], growth factors, and inflammatory 
cytokines [45]. Oral administration of Zn(ASA)2 protects 
the heart from pronounced hypertrophy of single cardio-
myocytes. However, the LV wall thickness, assessed by 
echocardiography, did not significantly differ among the 
groups.
Metabolic disturbance in diabetes contribute to the 
development of DCM. Impaired cardiac function, due 
to cardiomyocyte hypertrophy, apoptosis, and fibrosis 
has been well documented in the setting of DCM [46]. 
Additionally, high glucose has been shown to exert det-
rimental effects on the myocardial contractile function in 
ZDF rats [47]. In the present study, with the use of in vivo 
cardiac catheterization and LV pressure–volume analysis, 
we showed that the slope Ees of ESPVR, as a load-insen-
sitive index of contractility, was only slightly decreased in 
the diabetic rats. In consonance with our observations, 
Fig. 6 Effect of Zn(ASA)2 on myocardial fibrosis and DNA‑strand breaks in cardiomyocytes. Representative photomicrographs showing the whole‑
slide after a the region of interest detection and b pixelwise classification of the tissue; blue fibrotic areas, green normal tissue, orange excluded areas 
in the acid fuchsin orange G (AFOG) stained sections. c Quantitative analysis of interstitial fibrosis in the myocardium. Representative photomicro‑
graphs of d nuclei with 4′,6‑diamidino‑2phenylindole (DAPI‑stained nuclei, blue); e nuclei with fragmented DNA visualized by Terminal Deoxynucle‑
otidyl Transferase‑Mediated dUTP Nick End‑Labeling (TUNEL) staining (TUNEL‑positive nuclei, red), and f merged image (red/blue double stained) 
(magnification ×400, scale bar: 50 µm) from the same sample which belong to the ZDF group. g Quantification of TUNEL‑positive cells for each 
group. Values are mean ± SEM, n = 6–10. *P < 0.05 vs ZL, #P < 0.05 vs ZDF, $P < 0.05 vs Zn(ASA)2. Zn(ASA)2 indicates a zinc complex of acetylsalicylic 
acid, ZDF Zucker diabetic fatty rats, ZL Zucker lean
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our previous studies showed that LV contractility, with 
the use of load-independent variables, was not severely 
impaired in type-2 diabetic animals [24, 25]. Additionally, 
it has been shown that ZDF rats exhibited LV diastolic 
dysfunction [24], and that subclinical LV diastolic dys-
function is already present in the early phase of disturbed 
glucose metabolism, before the onset of type-2 DM, 
being mainly associated with the state of insulin resist-
ance and not only with sustained hyperglycemia [48]. The 
administration of drugs that may reduce insulin resist-
ance and related cardiovascular risk, would be useful in 
patients with type-2 DM at risk for developing DCM. 
In the present work, diabetes associated changes to the 
indexes of LV diastolic stiffness (LVEDP and slope of 
Fig. 7 Effects of Zn(ASA)2 on myocardial protein expression. Immunoblot analysis for a CD36, b insulin receptor (IR)‑β, c glucose transporter (GLUT)‑
4, d phosphorylated PI3K, e PI3K, f phosphorylated phosphatidylinositol 3‑kinase‑(PI3K)/PI3K ratio, g phosphorylated, h total AKT and i phosphoryl‑
ated AKT/total Akt ratio protein band densities in the myocardium. Glyceraldehyde‑3‑phosphate dehydrogenase (GAPDH), housekeeping protein 
was used as reference. Values are mean ± SEM, n = 6–7. *P < 0.05 vs ZL, #P < 0.05 vs ZDF, $P < 0.05 vs Zn(ASA)2. Zn(ASA)2 indicates a zinc complex of 
acetylsalicylic acid, ZDF Zucker diabetic fatty rats, ZL Zucker lean
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EDPVR) were significantly higher in type-2 diabetic rats, 
reflecting the impairment of passive, rather than active, 
LV diastolic function. The LV diastolic dysfunction was 
improved by Zn(ASA)2 treatment. Even though Xie and 
al. have shown only minor electrophysiological changes 
(in action potential duration and conduction velocity) 
during normoxic perfusion in 13–16  weeks old Zucker 
obese diabetic fatty rats [49], in the present study rats 
of the diabetic group presented a delayed repolarization 
of the ventricular myocardium manifested in prolonged 
QT intervals on the surface ECG, which was attenu-
ated by a Zn(ASA)2 treatment. Our results showed that 
Zn(ASA)2 administration reduces the risk for ventricular 
tachyarrhythmia.
Being a key component of the insulin signaling pathway 
and its downstream targets, including serine/threonine 
protein kinase AKT, mammalian target of rapamycin 
(mTOR), and glycogen synthase kinase (GSK), PI3K plays 
important roles in cardiac adaptation including protein 
synthesis, inhibition of apoptosis, and fatty acid and 
glucose metabolism, as well as in gene expression and 
cell survival. In DM advanced glycation endproducts 
(AGEs)/receptor for AGEs interaction (RAGE) has been 
shown to contribute to the development of DCM [50]. A 
recent study indicates that AGEs trigger cardiomyocyte 
autophagy (a type II programmed cell death) by at least in 
part inhibiting the PI3K/AKT/mTOR pathway via RAGE 
[51]. The activation of the PI3K signaling increases ser-
ine phosphorylation of protein kinase B, and this results 
in the uptake of glucose by inducing the translocation of 
the GLUT-4 protein to the cell membrane. In the present 
study, the ratios of expression of phosphorylated AKT 
to total AKT, as measured by densitometry of Western 
blot, were significantly lower in heart samples from dia-
betic animals. The oral treatment of rats with Zn(ASA)2 
reversed this alteration to the levels observed in ZL rats. 
It has been recently shown that zinc supplementation can 
rescue the detrimental effects of Akt2 gene deletion on 
the heart, probably associated with its insulin mimetic 
effect on the cardiac glucose-metabolism [52]. In the pre-
sent study even though diabetes resulted in a reduction 
in myocardial GLUT-4 protein expression, a Zn(ASA)2 
treatment had no effect upon this factor. The down-regu-
lation of GLUT4 expression in the heart has been postu-
lated to contribute to the altered substrate utilization and 
impaired contractility observed in diabetic cardiomyo-
pathy [53]. Additionally, observations in GLUT4-defi-
cient mice indirectly suggest that a down-regulation of 
GLUT4 may be involved in the pathogenesis of hypertro-
phy [54]. As our results showed that Zn(ASA)2 improves 
LV diabetic heart function not by decreasing myocardial 
hypertrophy but likely by its action on fibrosis, these 
observations may in part, explain why the Zn(ASA)2 
treatment failed to regulate the expression of myocardial 
GLUT4 protein. All together, AKT activation seems to 
play a key role in the cardioprotective effects of Zn(ASA)2 
against the DCM.
However some limitations of this study need to be 
addressed. ZDF rats represent a progressive and severe 
type-2 DM with diabetic complications that were left 
untreated until 25–26 weeks of age. We did not investi-
gate whether improving metabolic control with a tra-
ditional oral antidiabetic treatment could also prevent 
diabetic cardiomyopathy. Additionally, the ZDF strain 
is an inbred rat model produced by a mutation in the 
leptin-receptor gene, whereas leptin deficiencies are not 
common in humans. However, ZDF rats were selected as 
an appropriate diabetic experimental model to verify the 
present study’s hypothesis.
Conclusions
In summary, the oral administration of Zn(ASA)2 not 
only decreases blood glucose levels, but also alleviates 
type-2 diabetes-induced damage in rat cardiac tissue, 
in part via the activation of the myocardial AKT signal-
ling pathway. We recently showed that Zn(ASA)2 pro-
tects the heart against myocardial ischemia in rats [22]. 
As a whole, our results suggest that Zn(ASA)2 might be 
an ideal therapeutic strategy for diabetic patients at risk 
for ischemic heart disease. Further detailed studies are 
required to reveal the exact mechanisms underlying 
Zn(ASA)2′s protective effects.
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